Document:

Unassociated Document

    EXHIBIT
      4.1 (c)

    

    AGREEMENT
      AND AMENDMENT NO. 2 OF THE DISTRIBUTION AGREEMENT DATED FEBRUARY 25,
      2004

    

    

    
      	
              Between :

            	
              -
                EDAP TMS S.A., a French société
                anonyme having
                its registered office at Parc d'activité La Poudrette Lamartine, 4-6, rue
                du Dauphiné , 69120 Vaulx-en-Velin, France (“EDAP
                TMS”)

            
	 	 
	 	
              -
                EDAP S.A., a French société
                anonyme having
                its registered office at 4-6, rue du Dauphiné , 69120 Vaulx-en-Velin,
                France (“EDAP”)

            
	 	 
	 	
              -
                Technomed Medical Systems S.A., a French société
                anonyme having
                its registered office at 4-6, rue du Dauphiné , 69120 Vaulx-en-Velin,
                France (“Technomed”)

               

              (collectively,
                the “EDAP
                Parties”)

              On
                the one hand, 

            
	 	 
	
              And
                :

            	
              HT
                Prostate Therapy Management Company L.L.C., a limited liability company
                incorporated under the laws of Delaware (United States), having
                its registered office at 1841 West Oak Parkway,
                Suite A, Marietta, GA 30062, United
                States (“HT
                Prostate”)

              On
                the other hand,

            

    

    

     

    WHEREAS,
      the
      parties entered into a Distribution Agreement as of February 25, 2004, which
      contemplated, inter
      alia,
      the
      issuance of warrants by EDAP TMS in favor of HT Prostate;

     

    WHEREAS,
      the parties entered into an amendment to the Distribution Agreement (Amendment
      No. 1) as of December 23, 2004, which waived the exclusivity on the use of
      Ablatherm related trademarks prior to receipt of the PMA;

     

    WHEREAS,
      acting
      upon delegation granted to it by the general meeting of the shareholders of
      EDAP
      TMS held on January 29, 2004, the board of directors of EDAP TMS issued, on
      January 28, 2005, 1,000,000 (one million) warrants (bons
      de souscription d’actions)
      divided
      into seven categories (categories A to G), with each warrant giving its holder
      the right to subscribe one share of EDAP TMS upon certain conditions (the
“Warrants”),
      including (without limitation):

     

    
      	 	
              -

            	
              100,000
                warrants of category D, which may be exercised as from January 1,
                2006 if
                HT Prostate Therapy Management
                Company L.L.C. or any other Healthtronics Company purchases from
                EDAP TMS
                or its subsidiaries, at least four (4) lithotripters in
                2005 (“Warrants
                D”); 

            

    

     

    
      	 	
              -

            	
              100,000
                warrants
                of category E,
                which may be exercised as from January 1, 2007 if HT Prostate Therapy
                Management
                Company L.L.C. or any other Healthtronics Company purchases from
                EDAP TMS
                or its subsidiaries, at least four (4) lithotripters in
                2006 (“Warrants
                E”);

            

    

     

    
      	 	
              -

            	
              100,000
                warrants
                of category F, which
                may be exercised as from January 1, 2008 if HT Prostate Therapy
                Management
                Company L.L.C. or any other Healthtronics Company purchases from
                EDAP TMS
                or its subsidiaries, at least four (4) lithotripters in 2007
                (“Warrants
                F”).
                

            

    

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    WHEREAS,
      given
      the fact that HT Prostate wishes to focus its efforts on obtaining the PMA
      for
      Ablatherm and on developing the HIFU market potential on the US territory,
      and
      does not want to pursue the distribution of EDAP's lithotriptors in the US,
      the
      Parties wish to amend the terms and conditions of Warrants D, Warrants E and
      Warrants F as follows:

     

    

    Article
      1

    

    HT
      Prostate, as sole holder of all Warrants E and Warrants F, hereby definitively
      and irrevocably waives any and all rights that it may have to exercise, now
      or
      in the future, the Category E Warrants and Category F Warrants that were issued
      to it, and consequently hereby acknowledges and agrees that all Category E
      and
      Category F Warrants are thus null and void, which shall be acknowledged by
      EDAP
      TMS. 

    

    Article
      2

    

    The
      EDAP
      Parties hereby acknowledge HT Prostate’s definitive and irrevocable waiver of
      all rights to exercise the Category E and Category F Warrants, and that EDAP
      TMS
      will thus declare and acknowledge that such Warrants have become null and
      void.

    

    Article
      3

    

    HT
      Prostate, as sole holder of all Category D Warrants, and the EDAP Parties agree
      to amend the conditions upon which Category D Warrants may be exercised as
      follows:

    

    “Warrants
      D may be exercised as from January 1, 2006 if, in 2005, HT Prostate Therapy
      Management
      Company L.L.C. or any other Healthtronics Company (i) purchases from EDAP TMS
      or
      its subsidiaries at least two (2) lithotripters, and (ii) places an irrevocable
      order to EDAP TMS or its subsidiaries for the purchase of one (1) Ablatherm
      at a
      net price equal to USD 490,000”
      ;

    

    it
      being
      specified that such amendment is subject to, and will be effective upon, a
      decision by the board of directors of EDAP TMS to adopt such amendment.

    

    Article
      4

    

    HT
      Prostate, as sole holder of all Category D, Category E and Category F Warrants,
      hereby
      agrees and undertakes to reiterate its decisions contained in Articles 1 to
      3
      above in separate documents (including minutes or “procès-verbaux”)
      upon
      the request of EDAP TMS, as may be appropriate in light of French corporate
      law
      requirements and other relevant formalities.

    

    Article
      5

    

    
      	
              5.1

            	
              As
                a result of the foregoing provisions, and subject to the
                decision by the board of directors of EDAP TMS to adopt the amendment
                set
                forth in Article 3 above, the
                Parties hereby agree to amend the Distribution Agreement as follows,
                which
                amendment shall become effective upon adoption of the amendment referred
                to in Article 3 above:

            

    

    

    (a) the
      minutes of the Board of Directors relating thereto will be attached as a new
      Exhibit E to the Distribution Agreement.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (b) the
      following sentence shall be added at the end of Section 12.1(a) of the
      Distribution Agreement: 

     

    “The
      Warrant Exercise Milestone relating to the Warrants of category D, as set forth
      in the resolution of the Board of Directors dated January 28, 2005, as per
      Exhibit A, is amended as reflected in a new resolution of the Board of Directors
      of the Parent Corporation set forth as Exhibit E. In addition, HT Prostate
      has
      waived any and all rights it may have under the 100,000 Category E Warrants
      and
      the 100,000 Category F Warrants that it holds, which have become null and void
      and may no longer be exercised, as is also reflected in a resolution of the
      Board of Directors of the Parent Corporation set forth in Exhibit
      E.”
      

     

    
      	
              5.2

            	
              Except
                as amended in Article 5.1 above, all of the provisions of the Distribution
                Agreement remain in full force and
                effect.

            

    

    

    

    IN
      WITNESS WHEREOF, the
      undersigned have executed this Agreement on December 29, 2005.

    

    

    
      	
              EDAP
                TMS S.A.

               

               

              S/
                HUGUES DE BANTEL
                
                

              

              By:
                Hugues de Bantel

              Title:
                Directeur
                Général

               

            	
              EDAP
                S.A.

               

               

              S/
                HUGUES DE BANTEL
                
                

              

              By:
                Hugues de Bantel

              Title:
                Président
                - Directeur Général

            
	 	 
	
              TECHNOMED
                MEDICAL SYSTEMS S.A.

               

               

              S/
                HUGUES DE BANTEL
                
                

              

              By:
                Hugues de Bantel

              Title:
                Président - Directeur Général

            	
              HT
                PROSTATE THERAPY MANAGEMENT LLC

               

               

              S/
                CHRISTOPHER SCHNEIDER
                
                

              

              By:
                Christopher Schneider 

              Title:
                President, Medical Devices

            

    

    

    
 

    3EX-10.1

WPT ENTERPRISES, INC.

AMENDMENTS TO THE 2004 STOCK INCENTIVE PLAN

MAY 31, 2006

The 2004 Stock Incentive Plan is hereby amended as follows:

(a) Section 5.1 is hereby amended and restated as follows:

5.1. Number of Shares. Subject to adjustment as provided in Section 10.6, the
number of shares of Common Stock which may be issued under the Plan shall not exceed
4,200,000 shares of Common Stock. Shares of Common Stock that are issued under the Plan or
are subject to outstanding Incentives will be applied to reduce the maximum number of shares
of Common Stock remaining available for issuance under the Plan.

(b) The following Section 10.14 is hereby added:

10.14. Change in Control. (a) Upon a Change in Control, as defined in paragraph
(b) of this Section 10.14, any stock option or restricted stock award granted to any
Participant under this Plan that would have become vested upon continued employment by the
Participant shall immediately vest in full and become exercisable, notwithstanding any
provision to the contrary of such award, and notwithstanding the discretion of the Committee
pursuant to Section 10.12.

(b) For purposes of this Section 10.14, “Change in Control” means:

(1) The acquisition by any person, entity or “group”, within the meaning of Section
13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934 (the “Exchange Act”) (excluding,
for this purpose, (A) the Company, (B) any employee benefit plan of the Company or its
subsidiaries which acquires beneficial ownership of voting securities of the Company or (C)
Lakes Entertainment, Inc., Lakes Poker Tour, LLC or any other entity at least 80% of the
voting equity of which is owned by Lakes Entertainment, Inc.) of beneficial ownership
(within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 33% or more of
either the then outstanding shares of common stock or the combined voting power of the
Company’s then outstanding voting securities entitled to vote generally in the election of
directors; or

(2) Individuals who, as of May 31, 2006, constitute the Board (the “Incumbent Board”)
cease for any reason to constitute at least a majority of the Board, provided that any
person becoming a director subsequent to May 31, 2006 whose election, or nomination for
election by the Company’s stockholders, was approved by a vote of at least a majority of the
directors then comprising the Incumbent Board (other than an election or nomination of an
individual whose initial assumption of office is in connection with an actual or threatened
election contest relating to the election of the Directors of the Company, as such terms are
used in Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) shall be, for
purposes of this Agreement, considered as though such person were a member of the Incumbent
Board; or

(3) Approval by the stockholders of the Company of (A) a reorganization, merger or
consolidation, in each case, with respect to which persons who were the stockholders of the
Company immediately prior to such reorganization, merger or consolidation do not,
immediately thereafter, own more than 50% of the combined voting power of the reorganized,
merged or consolidated company’s then outstanding voting securities entitled to vote
generally in the election of directors of the reorganized, merged or consolidated company,
or (B) a liquidation or dissolution of the Company or (C) the sale of all or substantially
all of the assets of the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]